Therapeutics Acquisition Corp (RACA) to Combine with POINT Biopharma in $639M Deal

Therapeutics, doing-business-as Research Alliance Corp. I (NASDAQ:RACA), has entered into a definitive agreement to combine with POINT Biopharma at an enterprise value of $639.2 million. POINT is a clinical stage radiopharmaceutical firm researching the use of radioglands to treat cancer before and during chemotherapy. The combined entity is expected to trade on the Nasdaq under
Read More